No photo of Seema Singhal

View Scopus Profile

Seema Singhal

  • 14579 Citations
1990 …2020
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Myeloma, Transplantation

Certifications and Licenses

Internal Medicine

Training Experience

1991Residency, Bombay University, India
1992Fellowship, Hadassah University Hospital, Israel

Education/Academic qualification

MD, Bombay University

… → 1991

Research interests

  • Amyloidosis
  • Monoclonal Antibodies
  • Multiple Myeloma
  • Plasma Cell Disorders
  • Stem Cell Transplant
  • Waldenstroms

Fingerprint Dive into the research topics where Seema Singhal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 20 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Autologous Transplantation Medicine & Life Sciences
Bone Marrow Transplantation Medicine & Life Sciences
Homologous Transplantation Medicine & Life Sciences
Transplants Medicine & Life Sciences
Hematopoietic Stem Cell Transplantation Medicine & Life Sciences
Melphalan Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2003 2020

Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

Singhal, S.

Merck Sharp & Dohme Corp.

1/26/17 → 1/26/20

Project: Research project

Prot# X05211: A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma (NU Prot# NU 06H1)

Frankfurt, O., Gordon, L. I., Kuzel, T. M., Mehta, J., Singhal, S. & Winter, J. N.

Millennium Pharmaceuticals, Inc

6/29/06 → 1/31/20

Project: Research project

Prot #NEOD001-CL002: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

Singhal, S.

Covance Inc., Prothena Therapeutics Limited

12/11/15 → 12/11/18

Project: Research project

Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to

Singhal, S.

Janssen Research & Development, LLC

10/23/15 → 10/23/18

Project: Research project

Prot #ARRAY-520-215:A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

Singhal, S.

ICON Clinical Research, LLC, Array BioPharma Inc.

5/5/15 → 5/5/18

Project: Research project

Research Output 1990 2019

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Kumar, S. K., Callander, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, K., Holmberg, L., Htut, M., Huff, C. A., Kang, Y., Landgren, O., Malek, E. & 11 others, Martin, T., Omel, J., Raje, N., Sborov, D., Singhal, S., Stockerl-Goldstein, K., Tan, C., Weber, D., Johnson-Chilla, A., Keller, J. & Kumar, R., Oct 1 2019, In : Journal of the National Comprehensive Cancer Network : JNCCN. 17, 10, p. 1154-1165 12 p.

Research output: Contribution to journal › Article

Open Access
Multiple Myeloma
Guidelines
Aftercare
Paraproteinemias
Plasmacytoma
3 Citations (Scopus)

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

KEYNOTE-183 Investigators, Sep 1 2019, In : The Lancet Haematology. 6, 9, p. e459-e469

Research output: Contribution to journal › Article

Multiple Myeloma
Dexamethasone
United States Food and Drug Administration
Disease-Free Survival
Myocarditis
1 Citation (Scopus)

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Stewart, A. K., Krishnan, A. Y., Singhal, S., Boccia, R. V., Patel, M. R., Niesvizky, R., Chanan-Khan, A. A., Ailawadhi, S., Brumm, J., Mundt, K. E., Hong, K., McBride, J., Shon-Nguyen, Q., Xiao, Y., Ramakrishnan, V., Polson, A. G., Samineni, D., Leipold, D., Humke, E. W., McClellan, J. S. & 1 others, Berdeja, J. G., Feb 1 2019, In : Blood cancer journal. 9, 2, 17.

Research output: Contribution to journal › Article

Multiple Myeloma
Anti-Idiotypic Antibodies
Maximum Tolerated Dose
Antibodies
Pharmaceutical Preparations
35 Citations (Scopus)

Multiple Myeloma, version 3.2018: Featured updates to the NCCN guidelines

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kang, Y., Kassim, A., Liedtke, M., Malek, E., Martin, T. & 10 others, Neppalli, V. T., Omel, J., Raje, N., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Weber, D., Yahalom, J., Kumar, R. & Shead, D. A., Jan 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 1, p. 11-20 10 p.

Research output: Contribution to journal › Review article

Multiple Myeloma
Guidelines
Aftercare
Therapeutics

Clinical practice guidelines in oncology

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C. A., Kassim, A., Liedtke, M., Martin, T., Omel, J., Raje, N. & 9 others, Reu, F. J., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Treon, S. P., Weber, D., Yahalom, J., Shead, D. A. & Kumar, R., Feb 1 2017, In : JNCCN Journal of the National Comprehensive Cancer Network. 15, 2, p. 230-269 40 p.

Research output: Contribution to journal › Article

Multiple Myeloma
Practice Guidelines
Plasma Cells
Waldenstrom Macroglobulinemia
Paraproteinemias